Τίτλος:
Effect of a low dose combined oral contraceptive pill on the hormonal profile and cycle outcome following COS with a GnRH antagonist protocol in women over 35 years old
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
This prospective study examines if pre-treatment with two different doses of an oral contraceptive pill (OCP) modifies significantly the hormonal profile and/or the IVF/ICSI outcome following COS with a GnRH antagonist protocol. Infertile patients were allocated to receive either OCP containing 0.03mg of ethinylestradiol and 3mg of drospirenone, or OCP containing 0.02mg of ethinylestradiol and 3mg of drospirenone prior to initiation of controlled ovarian stimulation (COS) with recombinant gonadotropins on a variable multi-dose antagonist protocol (Ganirelix), while the control group underwent COS without OCP pretreatment. Lower dose OCP was associated with recovery of FSH on day 3 instead of day 5, but the synchronization of the follicular cohort, the number of retrieved oocytes and the clinical pregnancy rate were similar to higher dose OCP. © 2014 Informa UK Ltd. All rights reserved.
Συγγραφείς:
Bakas, P.
Hassiakos, D.
Grigoriadis, C.
Vlahos, N.F.
Liapis, A.
Creatsas, G.
Περιοδικό:
Gynecological Endocrinology
Εκδότης:
Informa Healthcare
Λέξεις-κλειδιά:
drospirenone; ethinylestradiol; follitropin; ganirelix; androstane derivative; drospirenone; ethinylestradiol; follitropin; ganirelix; gonadorelin; hormone antagonist; oral contraceptive agent, adult; Article; cell synchronization; comparative study; controlled ovarian stimulation; controlled study; disease duration; down regulation; drug effect; embryo; endometrium; female; female infertility; hormonal therapy; human; low drug dose; major clinical study; oocyte retrieval; outcome assessment; pregnancy rate; stimulation; transvaginal echography; ultrasound scanner; analogs and derivatives; antagonists and inhibitors; blood; drug administration; drug effects; menstrual cycle; ovulation induction; pregnancy; procedures; treatment outcome, Adult; Androstenes; Contraceptives, Oral, Combined; Drug Administration Schedule; Ethinyl Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Menstrual Cycle; Ovulation Induction; Pregnancy; Pregnancy Rate; Treatment Outcome
DOI:
10.3109/09513590.2014.932343
